Payers, providers, patients and pharma companies all want to understand the value of specific treatments – and patient registries can help them do that.
Payers, providers, patients and pharmaceutical companies all want to understand the value of specific treatments – and patient registries can help them do that. These online data platforms give patients and providers a single place to record information about diagnosis, condition and treatment experience.
Registries are already being used by stakeholders across the industry to define value, both clinically and economically, in an effort to improve the overall quality of care for current and future patients in a variety of ways:
• Providers and hospital systems can use the data to demonstrate their quality of care, improve the clinical outcomes of patients and enable personalized medicine through genetic testing to define more narrow target patient populations
• Payers can use them to evaluate the quality and cost of care for increasingly narrow subsets of patients
• Pharmaceutical and medical device companies can use them to demonstrate the value of their products and services, and bring new products to the market more quickly and with a higher likelihood of clinical and economic success.
• All stakeholders can harness these data sources to achieve these goals with greater ease and lower costs.
Standardization is the next step
Going forward registries will play an even greater role as hubs that bring together communities of patients, providers and payers to gather and share real world evidence insights from clinical, economic and observational data to support both clinical care optimization as well as drug development. However, as with all digital patient data, the industry continues to struggle with how we can scale the benefits of registries to ensure this information can be shared and accessed by all of the stakeholders who can benefit, while protecting patients’ privacy and confidentiality. Creating interoperability between registries is a challenge that won’t be easily solved, but we can achieve incremental improvements through the standardization of registries.
In many cases, large provider organizations and professional associations have more than one registry, each started by different groups using different data sets. To gain efficiencies, these organizations can develop a common data model for all of their registries for use on an integrated platform. This enables stakeholders to look at the same patient across multiple registries, and leverage and reuse the data to greater benefit. It also allows them to examine data from an enterprise standpoint, and to enable the input of electronic health records (EHRs) into the registries.
At the hospital and provider levels, this has the potential to help with quality improvement registries, which are currently labor intensive. Current registries require a huge amount of manual data entry which can limit their adoption and ability to scale. Hospitals and providers can automate some of these steps by harnessing the modern electronic record infrastructure developed to support EHRs enabling them to increase external integration and interoperability. Further gains can be made by improving workflows and data governance at the hospital and enterprise levels.
Data integration and standardization are key to unlocking the productivity puzzle in the world of registries. When we achieve these goals we enable access to a vast store of information and analytics opportunities to more gain greater insights into ways to improve clinical care and patient research. To do this, data must be pulled from multiple sources in a consistent manner, including EHR data, patient data and research and financial information from trials and payers. The concept of real-world evidence hubs centered on disease-specific communities that aggregate these data sources holds great promise as healthcare stakeholders work to demonstrate value. These hubs can form the basis of the “registry of the future” – leveraging data already stored in EHRs to create an information framework for answering healthcare stakeholders’ questions about how to measure and improve the quality of care.
Brian Kelly is President, Payer & Provider Services at Quintiles.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.